Panitumumab Dosage
This dosage information may not include all the information needed to use Panitumumab safely and effectively. See additional information for Panitumumab.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Colorectal Cancer
6 mg/kg administered as an intravenous infusion over 60 minutes every 14 days
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
The infusion rate should be reduced by 50% in patients experiencing a mild or moderate (grade 1 or 2) infusion reaction for the duration of that infusion.
Panitumumab infusion should be immediately and permanently discontinued in patients experiencing severe (grade 3 or 4) infusion reactions.
Panitumumab should be withheld if a patient has dermatologic toxicities that are grade 3 or higher or are considered intolerable. If toxicity does not improve to less than or equal to grade 2 within one month, then permanently discontinue panitumumab.
If dermatologic toxicity improves to less than or equal to grade 2, and the patient is symptomatically improved after withholding no more than two doses of panitumumab, then treatment may be resumed at 50% of the original dose. If toxicities recur, then panitumumab should be permanently discontinued. If toxicities do not recur, subsequent doses of panitumumab may be increased by increments of 25% of the original dose until the recommended dose of 6 mg/kg is reached.
Precautions
Appropriate medical resources for the treatment of severe infusion reactions should be available during panitumumab infusions.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Dialysis
Data not available
